Indie Asset Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-14,101
Closed -$374K 112
2024
Q4
$374K Sell
14,101
-1,559
-10% -$42.3K 0.29% 56
2024
Q3
$453K Sell
15,660
-283
-2% -$8.26K 0.34% 48
2024
Q2
$446K Sell
15,943
-425
-3% -$11.7K 0.36% 43
2024
Q1
$454K Buy
16,368
+204
+1% +$5.66K 0.4% 40
2023
Q4
$465K Buy
16,164
+101
+0.6% +$3.05K 0.42% 34
2023
Q3
$533K Hold
16,063
0.54% 26
2023
Q2
$589K Hold
16,063
0.64% 25
2023
Q1
$655K Sell
16,063
-2,625
-14% -$113K 0.77% 24
2022
Q4
$958K Hold
18,688
1.05% 12
2022
Q3
$818K Sell
18,688
-370
-2% -$18K 0.84% 16
2022
Q2
$999K Sell
19,058
-350
-2% -$17.8K 0.88% 14
2022
Q1
$1M Sell
19,408
-780
-4% -$40.5K 0.76% 17
2021
Q4
$1.19M Sell
20,188
-1,443
-7% -$71.5K 0.87% 15
2021
Q3
$930K Buy
21,631
+1,405
+7% +$62.2K 0.75% 23
2021
Q2
$792K Sell
20,226
-1,700
-8% -$66.1K 0.64% 25
2021
Q1
$794K Sell
21,926
-1,435
-6% -$51K 0.9% 23
2020
Q4
$860K Sell
23,361
-4,290
-16% -$157K 1% 20
2020
Q3
$963K Buy
27,651
+2,418
+10% +$84.8K 1.21% 18
2020
Q2
$919K Buy
25,233
+783
+3% +$26.6K 1.15% 17
2020
Q1
$757K Sell
24,450
-247
-1% -$8.42K 0.94% 22
2019
Q4
$918K Buy
+24,697
New +$880K 0.98% 22

Other funds holding PFE

Indie Asset Partners's PFE Position: Q1 2025 in Review

Indie Asset Partners sold out of Pfizer (PFE) in Q1 2025, closing a stake of 14,101 shares — an estimated $374K sold.

Indie Asset Partners first reported a position in PFE in Q4 2019 and held it in 21 quarters. The position peaked at $1.19M in Q4 2021. 2,930 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • Indie Asset Partners reported no remaining Pfizer position as of Q1 2025 after selling out during the quarter.
  • Indie Asset Partners sold 14,101 Pfizer shares in Q1 2025, an estimated $374K.
  • Indie Asset Partners first reported a position in Pfizer in Q4 2019 and held it in 21 quarters.
  • Indie Asset Partners's Pfizer position peaked at $1.19M in Q4 2021.
  • 2,930 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on Indie Asset Partners's 13F filing for Q1 2025, filed 7 May 2025.